{
    "root": "45497e1a-f081-4a81-8511-ab0734c911e6",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "BIZENGRI",
    "value": "20250307",
    "ingredients": [
        {
            "name": "Zenocutuzumab",
            "code": "AE72RB1W1X"
        },
        {
            "name": "histidine monohydrochloride monohydrate",
            "code": "X573657P6P"
        },
        {
            "name": "histidine",
            "code": "4QD397987E"
        },
        {
            "name": "trehalose dihydrate",
            "code": "7YIN7J07X4"
        },
        {
            "name": "polysorbate 20",
            "code": "7T1F30V5YH"
        },
        {
            "name": "water",
            "code": "059QF0KO0R"
        }
    ],
    "indications": "bizengri® bispecific her2- her3-directed antibody indicated treatment : adults advanced , unresectable metastatic non-small cell lung cancer ( nsclc ) harboring neuregulin 1 ( nrg1 ) gene fusion disease progression prior systemic therapy . * ( 1.1 ) adults advanced , unresectable metastatic pancreatic adenocarcinoma harboring neuregulin 1 ( nrg1 ) gene fusion disease progression prior systemic therapy . * ( 1.2 ) * indication approved accelerated approval based overall response rate duration response . continued approval indication may contingent upon verification description benefit confirmatory trial ( ) .",
    "contraindications": "select patients treatment bizengri based presence nrg1 gene fusion . ( 2.1 ) evaluate left ventricular ejection fraction ( lvef ) initiating bizengri . ( 2.2 ) recommended bizengri 750 mg every 2 weeks disease progression unacceptable toxicity . ( 2.3 ) administer premedications infusion reduce risk infusion-related . ( 2.4 ) administer intravenous infusion , dilution , 4 hours . ( 2.7 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "none .",
    "indications_original": "BIZENGRI® is a bispecific HER2- and HER3-directed antibody indicated for the treatment of: Adults with advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 ( NRG1 ) gene fusion with disease progression on or after prior systemic therapy.* ( 1.1 ) Adults with advanced, unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 ( NRG1 ) gene fusion with disease progression on or after prior systemic therapy.* ( 1.2 ) *This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",
    "contraindications_original": "Select patients for treatment with BIZENGRI based on the presence of an NRG1 gene fusion. ( 2.1 ) Evaluate left ventricular ejection fraction (LVEF) before initiating BIZENGRI. ( 2.2 ) The recommended dosage of BIZENGRI is 750 mg every 2 weeks until disease progression or unacceptable toxicity. ( 2.3 ) Administer premedications before each infusion to reduce the risk of infusion-related reactions. ( 2.4 ) Administer as an intravenous infusion, after dilution, over 4 hours. ( 2.7 )",
    "adverseReactions_original": "None."
}